Google’s venture arm recruits a Harvard/Tesaro vet to help plant the seeds for a second oncology R&D revolution
Oncology R&D has been exploding over the past 5 years, and now Google’s venture arm is preparing to place a few explosives to help with the revolution — relying on a new recruit in the Cambridge/Boston branch to assist in fostering the movement.
Eight months after the high-profile scientist and Agios founder David Schenkein started his third career act in biotech, teaming up with Krishna Yeshwant as a general partner in charge of the life sciences portfolio at GV, they’re bringing on board their second entrepreneur-in-residence to help strategize their approach to investing in cancer research. And he has some deep experience in the oncology field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.